Literature DB >> 28378938

AG490 suppresses interleukin-34-mediated osteoclastogenesis in mice bone marrow macrophages.

Xin Cheng1, Qi-Long Wan1,2, Zu-Bing Li1,2.   

Abstract

Interleukin-34 (IL-34) has been recently identified as a novel cytokine, substituting for the function of macrophage colony-stimulating factor (M-CSF), a pivotal osteoclastogenic factor involved in bone-related diseases (e.g., osteomyelitis of the jaws). However, the molecular mechanisms are not fully understood. This study aimed to explore the potential mechanism of IL-34 in receptor activator of NF-kB ligand (RANKL)-induced osteoclast formation. We found that IL-34 alone significantly maintained the survival of bone marrow macrophages (BMMs) and enhanced the expression of the osteoclast-related genes TRAP, Ctsk, and NFATc1, as well as TRAP-positive multinucleated cells combined with RANKL, which can be reversed by AG490. Conversely, AG490 did not affect the M-CSF-mediated osteoclastogenesis in the presence of RANKL. The protein expression of p-STAT3 in BMMs was enhanced by IL-34 combined with RANKL compared with RANKL alone, and AG490 inhibited the expression of p-SATA3 at protein level in the IL-34 plus RANKL group, resulting in significantly increased Smad7 expression. This study demonstrated for the first time that IL-34 may play a crucial role in RANKL-induced osteoclastogenesis by promoting the proliferation and differentiation of BMMs, stimulating p-STAT3 expression, and inhibiting the expression of Smad7 in the absence of M-CSF.
© 2017 International Federation for Cell Biology.

Entities:  

Keywords:  AG490; IL-34; STAT3; Smad7; differentiation; osteoclast

Mesh:

Substances:

Year:  2017        PMID: 28378938     DOI: 10.1002/cbin.10771

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  8 in total

1.  Exogenous adenosine activates A2A adenosine receptor to inhibit RANKL-induced osteoclastogenesis via AP-1 pathway to facilitate bone repair.

Authors:  Xin Cheng; Chengcheng Yin; Yongqiang Deng; Zubing Li
Journal:  Mol Biol Rep       Date:  2021-11-30       Impact factor: 2.316

Review 2.  Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.

Authors:  Haidi Bi; Xing Chen; Song Gao; Xiaolong Yu; Jun Xiao; Bin Zhang; Xuqiang Liu; Min Dai
Journal:  Front Med (Lausanne)       Date:  2017-12-20

Review 3.  Regulation of Osteoclast Differentiation by Cytokine Networks.

Authors:  Dulshara Sachini Amarasekara; Hyeongseok Yun; Sumi Kim; Nari Lee; Hyunjong Kim; Jaerang Rho
Journal:  Immune Netw       Date:  2018-02-07       Impact factor: 6.303

Review 4.  The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis.

Authors:  Javier Muñoz-Garcia; Denis Cochonneau; Stéphane Télétchéa; Emilie Moranton; Didier Lanoe; Régis Brion; Frédéric Lézot; Marie-Françoise Heymann; Dominique Heymann
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

5.  Low-dose IL-34 has no effect on osteoclastogenesis but promotes osteogenesis of hBMSCs partly via activation of the PI3K/AKT and ERK signaling pathways.

Authors:  Jianxiang Xu; Lifeng Fu; Jinwu Bai; Huiming Zhong; Zhihui Kuang; Chengwei Zhou; Bin Hu; Licheng Ni; Li Ying; Erman Chen; Wei Zhang; Jiaqi Wu; Deting Xue; Weixu Li; Zhijun Pan
Journal:  Stem Cell Res Ther       Date:  2021-05-04       Impact factor: 6.832

6.  Napabucasin Induces Mouse Bone Loss by Impairing Bone Formation via STAT3.

Authors:  Xiangru Huang; Anting Jin; Xijun Wang; Xin Gao; Hongyuan Xu; Miri Chung; Qinggang Dai; Yiling Yang; Lingyong Jiang
Journal:  Front Cell Dev Biol       Date:  2021-03-18

Review 7.  STAT3-mediated osteogenesis and osteoclastogenesis in osteoporosis.

Authors:  Xiaoli Hou; Faming Tian
Journal:  Cell Commun Signal       Date:  2022-07-25       Impact factor: 7.525

Review 8.  The M-CSF receptor in osteoclasts and beyond.

Authors:  Se Hwan Mun; Peter Sang Uk Park; Kyung-Hyun Park-Min
Journal:  Exp Mol Med       Date:  2020-08-17       Impact factor: 8.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.